⚠️ No article content returned.
HUTCHMED (China) Limited (HCM)

- Written by: Madison Wilson
Find more news, interviews, share price & company profile here for:
HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors.
HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET amplification.